Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and sales of the drug, casting doubts on the treatment’s future.

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Content by Methodist Health System. June is Alzheimer’s and Brain Awareness Month, which means there’s no better time to ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

More people in the U.S. South are prescribed a sought-after Alzheimer's-slowing drug compared to those in the Northeast, a ...

A study of mice and people looks at how the brain takes an experience, like being cut off in traffic, and responds with an ...

Over the past decade, Ralph got involved with the Maine Running Club and began signing up for more road races. When he ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live ...